Cover Image
市場調查報告書

全球經皮藥物遞輸市場

Global Transdermal Drug Delivery Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 307321
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
全球經皮藥物遞輸市場 Global Transdermal Drug Delivery Market 2014-2018
出版日期: 2014年06月30日 內容資訊: 英文 76 Pages
簡介

經皮藥物遞輸,在醫藥品產業中是大型還有順利成長的市場區隔。全球經皮藥物遞輸市場,預計從2013年到2018年,以9.92%的年複合成長率擴大。

本報告提供全球經皮藥物遞輸市場現狀與未來預測、市場成長因素與課題、主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 經皮藥物遞輸市場上競爭的評估

第8章 經皮藥物遞輸的最佳化

第9章 各應用領域的市場區隔

第10章 地理區分

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • ANI Pharmaceuticals Inc.
  • Antares Pharma Inc.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

第20章 相關報告

目錄
Product Code: IRTNTR3714

About Transdermal Drug Delivery

Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin.

TechNavio's analysts forecast the Global Transdermal Drug Delivery market will grow at a CAGR of 9.92 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: Smoking Cessation, Pain Management, Hormone Therapy, Cardiovascular Indications, and Others.

TechNavio's report, the Global Transdermal Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Transdermal Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • ANI Pharmaceuticals Inc.
  • Antares Pharma Inc.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Novartis AG

Other Prominent Vendors

  • 3M Pharmaceuticals Co.
  • Durect Corp.
  • Iontera Inc.
  • Isis Biopolymer Inc.
  • LTS Lohmann Therapie-Systeme AG
  • Mylan Laboratories Inc.
  • Nitto Denko Corp.
  • Pantec Biosolutions AG
  • Phosphagenics Ltd.
  • Tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd.

Key Market Driver

  • Increase in Number of Transdermal Drug Delivery Products

For a full, detailed list, view our report

Key Market Challenge

  • Availability of Alternatives

For a full, detailed list, view our report

Key Market Trend

  • Increase in R&D Activities

For a full, detailed list, view our report

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Competitive Assessment of Transdermal Drugs Delivery Market

08. Optimisation of Transdermal Drug Delivery

09. Market Segmentation by Application

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. ANI Pharmaceuticals Inc.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Strategy
    • 19.1.4. Business Segmentation
    • 19.1.5. Business Segmentation by Revenue 2013
    • 19.1.6. Business Segmentation by Revenue 2012 and 2013
    • 19.1.7. Key Developments
    • 19.1.8. SWOT Analysis
    • 19.1.9. Strengths
    • 19.1.10. Weaknesses
    • 19.1.11. Opportunities
    • 19.1.12. Threats
  • 19.2. Antares Pharma Inc.
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Strategy
    • 19.2.5. Segmentation by Products
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
    • 19.2.8. Strengths
    • 19.2.9. Weaknesses
    • 19.2.10. Opportunities
    • 19.2.11. Threats
  • 19.3. Bayer AG
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Strategy
    • 19.3.5. Sales Segmentation by Business
    • 19.3.6. Sales by Geographical Segmentation
    • 19.3.7. Key Information
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. Janssen Pharmaceuticals Inc.
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Strategy
    • 19.4.5. Key Developments
    • 19.4.6. SWOT Analysis
    • 19.4.7. Strengths
    • 19.4.8. Weaknesses
    • 19.4.9. Opportunities
    • 19.4.10. Threats
  • 19.5. Novartis AG
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Sales by Geography
    • 19.5.6. Business Strategy
    • 19.5.7. Key Developments
    • 19.5.8. SWOT Analysis
    • 19.5.9. Strengths
    • 19.5.10. Weaknesses
    • 19.5.11. Opportunities
    • 19.5.12. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Transdermal Drug Delivery Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Transdermal Drug Delivery Market by Application
  • Exhibit 4: Global Transdermal Drug Delivery Market Segmentation 2013
  • Exhibit 5: Global Transdermal Drug Delivery Market by Geographical Segmentation
  • Exhibit 6: ANI Pharmaceuticals Inc.: Business Segmentation 2013
  • Exhibit 7: ANI Pharmaceuticals Inc.: Business Segmentation by Revenue 2013
  • Exhibit 8: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 9: Business Segmentation of Anatres Pharma, Inc. (2013)
  • Exhibit 10: Segmentation of Pipeline Products of Antares Pharma Inc. (2013)
  • Exhibit 11: Segmentation of Marketed Products of Antares Pharma Inc. (2013)
  • Exhibit 12: Business Segmentation of Bayer AG 2013
  • Exhibit 13: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 14: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 15: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
  • Exhibit 16: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 17: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: Novartis AG: Sales by Geography 2013
Back to Top